keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of anti-TNF

keyword
https://www.readbyqxmd.com/read/29142473/genetic-associations-with-adverse-events-from-anti-tumor-necrosis-factor-therapy-in-inflammatory-bowel-disease-patients
#1
Daniel Lew, Soon Man Yoon, Xiaofei Yan, Lori Robbins, Talin Haritunians, Zhenqiu Liu, Dalin Li, Dermot Pb McGovern
AIM: To study the type and frequency of adverse events associated with anti-tumor necrosis factor (TNF) therapy and evaluate for any serologic and genetic associations. METHODS: This study was a retrospective review of patients attending the inflammatory bowel disease (IBD) centers at Cedars-Sinai IBD Center from 2005-2016. Adverse events were identified via chart review. IBD serologies were measured by ELISA. DNA samples were genotyped at Cedars-Sinai using Illumina Infinium Immunochipv1 array per manufacturer's protocol...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29069471/serious-infusion-related-reaction-after-rituximab-abatacept-and-tocilizumab-in-rheumatoid-arthritis-prospective-registry-data
#2
Jean-Hugues Salmon, Jeanne-Marie Perotin, Jacques Morel, Moustapha Dramé, Alain Cantagrel, Liana Euller Ziegler, Philippe Ravaud, Jean Sibilia, Isabelle Pane, Xavier Mariette, Jacques-Eric Gottenberg
Objective: The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics. Methods: We analysed data from three independent prospective registers, namely autoimmunity and rituximab, Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab), promoted by the French Society of Rheumatology and including patients with RA. SIRRs were defined by an occurrence during or within 24 h of an infusion and requiring discontinuation of treatment...
October 23, 2017: Rheumatology
https://www.readbyqxmd.com/read/29063464/diverse-patterns-of-anti-tnf-%C3%AE-induced-lupus-case-series-and-review-of-the-literature
#3
REVIEW
Ora Shovman, Shalev Tamar, Howard Amital, Abdulla Watad, Yehuda Shoenfeld
The induction of autoantibodies is common following therapy with anti-TNF-α agents. However, anti-TNF-α-induced lupus (ATIL) is rare. We assessed the clinical characteristics of three patients with inflammatory bowel disease (IBD) who were treated with infliximab and developed distinct subsets of ATIL. Also, we searched for similar cases in the published literature. We describe three patients with ATIL. The first patient had a classical drug-induced lupus (DIL) presented by thrombocytopenia that resolved after infliximab discontinuation...
October 23, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29056769/disease-activity-in-axial-spondyloarthritis-after-discontinuation-of-tnf-inhibitors-therapy
#4
Agata Sebastian, Patryk Wojtala, Łukasz Lubiński, Małgorzata Mimier, Arkadiusz Chlebicki, Piotr Wiland
OBJECTIVE: Use of tumour necrosis factor inhibitors (TNFi) has proved to be an important step forward in the treatment of axial spondyloarthritis (axSpA), but the duration of the therapy as well as the management in case of low disease activity (LDA) or remission are not clearly established. Currently, the identification of potential predictors associated with the treatment discontinuation is the basic purpose of many clinical studies. The aim of this study was to analyze the influence of the discontinuation of TNFi therapy on the disease activity in patients with low disease activity...
2017: Reumatologia
https://www.readbyqxmd.com/read/29042704/alternative-to-rituximab-therapy-for-a-patient-with-ankylosing-spondylitis-who-was-unable-to-continue-anti-tnf-therapy
#5
Eri Katsuyama, Hiroshi Wakabayashi, Ken-Ei Sada, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Keiji Ohashi, Haruki Watanabe, Takayuki Katsuyama, Sonia Zeggar, Mariko Narazaki, Noriko Tatebe, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada
We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.
October 2017: Acta Medica Okayama
https://www.readbyqxmd.com/read/29037899/the-management-of-first-line-biologic-therapy-failures-in-rheumatoid-arthritis-current-practice-and-future-perspectives
#6
REVIEW
Ennio Giulio Favalli, Maria Gabriella Raimondo, Andrea Becciolini, Chiara Crotti, Martina Biggioggero, Roberto Caporali
The introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs) has dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life setting about 30-40% of bDMARD treated patients experience drug discontinuation because of either inefficacy or adverse events. According to international recommendations, to date the best strategy for managing first-line bDMARD failures has not been defined yet and available data (especially on TNF inhibitors [TNFis]) seem to drive toward a personalized approach for the individual patient...
October 14, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29033821/certolizumab-pegol-induced-folliculitis-like-lichenoid-sarcoidosis-in-a-patient-with-rheumatoid-arthritis
#7
Hiroyuki Sakai, Wakana Nomura, Motoshi Sugawara
Anti-tumor necrosis factor α (TNF-α) biologic agents are used for treating refractory sarcoidosis. However, sarcoidosis-like epithelioid cell granulomas may develop during anti-TNF-α treatment. A 63-year-old man suffering from rheumatoid arthritis was treated with oral methotrexate and methylprednisolone for 4 years. He subsequently started biweekly subcutaneous injections of certolizumab pegol. Three months later, light red follicular papules developed on his chest and they spread over the trunk and bilateral upper arms...
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29027693/efficacy-and-safety-of-golimumab-in-crohn-s-disease-a-french-national-retrospective-study
#8
C Martineau, B Flourié, P Wils, T Vaysse, R Altwegg, A Buisson, A Amiot, G Pineton de Chambrun, V Abitbol, M Fumery, X Hébuterne, S Viennot, D Laharie, L Beaugerie, S Nancey, H Sokol
BACKGROUND: Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not been studied for this indication. AIM: To report the efficacy and safety of golimumab in CD. METHODS: Crohn's disease patients who received golimumab were identified in 12 French tertiary centres and were retrospectively analysed...
October 13, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28991107/discontinuation-of-biological-treatments-in-inflammatory-bowel-disease-a-concise-pragmatic-review
#9
Shomron Ben-Horin, Ren Mao, Yun Qiu, Minhu Chen
Despite the proven efficacy of biological drugs for inflammatory bowel disease, these therapies are costly and do carry some risks, providing incentive for exploring strategies to discontinue therapy in patients with prolonged remission. We presently review multiple cohort studies indicating the overall risk of relapse after stopping an anti-tumor necrosis factor (TNF) in inflammatory bowel disease patients is roughly 40% at 12 months after therapy cessation. Despite methodological differences across studies, it appears that patients without deep remission (ie, patients with endoscopic or biomarker evidence of inflammation) are at increased risk of relapse after stopping anti-TNF, as are those with high-adequate levels of anti-TNF before stopping...
September 29, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28917981/intranasal-insulin-treatment-alleviates-methamphetamine-induced-anxiety-like-behavior-and-neuroinflammation
#10
Elmira Beirami, Shahrbanoo Oryan, Seyedeh Masoumeh Seyedhosseini Tamijani, Abolhassan Ahmadiani, Leila Dargahi
Insulin, as a peptide hormone, has recently gained attention for its pro-cognitive, anti-inflammatory and neuroprotective effects in the central nervous system (CNS). Most studies have indicated anxiogenic and neuroinflammatory effects of methamphetamine (MA) and other psychostimulants, even after periods of abstinence. The present study aimed to examine whether intranasal (IN) insulin treatment with high CNS bioavailability and minimal systemic side effects, can reverse the anxiety-like behavior and neuroinflammation induced by repeated MA administration...
November 1, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28901727/retention-rates-of-adalimumab-etanercept-and-infliximab-as-first-line-biotherapy-agent-for-rheumatoid-arthritis-patients-in-daily-practice-auvergne-experience
#11
Martin Soubrier, Bruno Pereira, Thomas Frayssac, Angelique Fan, Marion Couderc, Sandrine Malochet-Guinamand, Sylvain Mathieu, Zuzana Tatar, Anne Tournadre, Jean-Jacques Dubost
OBJECTIVE: To compare, in real-life conditions, the retention rates of anti-tumor necrosis factor (anti-TNF) treatment (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) initiated as first-line biotherapy for rheumatoid arthritis (RA) and to evaluate, in case of failure, the switch to another anti-TNF or a non-anti-TNF biological. METHODS: Monocentric retrospective cohort including all patients with RA starting a first anti-TNF between 2001 and 2015. RESULTS: Among the 346 patients analyzed, 201 received ETN, 82 ADA and 63 IFX...
September 13, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28861167/can-rheumatoid-arthritis-ever-cease-to-exist-a-review-of-various-therapeutic-modalities-to-maintain-drug-free-remission
#12
Di Liu, Na Yuan, Guimei Yu, Ge Song, Yan Chen
Therapies for rheumatoid arthritis (RA) were mostly aimed at reducing the pain, stiffness and further progression of joint destruction. However, with the advent of biologic agents that act against specific inflammatory cytokines contributing to RA pathogenesis (treat-to-target strategy), the degree of remission achieved has been remarkably impressive. In particular, inhibition of tumor necrosis factor α (TNFα), interleukins-1 and -6 and receptor-activator of nuclear kappa B ligand by neutralizing antibodies in early diagnosed RA patients has resulted in lowering of disease activity to levels that enable them to function as in the pre-disease stage...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28858070/anti-tnf-%C3%AE-use-during-the-third-trimester-of-pregnancy-in-women-with-moderate-severe-inflammatory-bowel-disease-and-the-risk-of-preterm-birth-and-low-birth-weight
#13
Heidi Kammerlander, Jan Nielsen, Torben Knudsen, Jens Kjeldsen, Sonia Friedman, Bente Mertz Nørgård
BACKGROUND: Little knowledge exists about the association between anti-tumor necrosis factor-alpha (anti-TNF-α) therapy for inflammatory bowel disease during late pregnancy and adverse birth outcomes. We aimed to examine whether treatment with anti-TNF-α during the third trimester affected preterm birth and low birth weight (LBW), compared with women who discontinued anti-TNF-α therapy before the third trimester. METHODS: We identified a nationwide cohort of 219 women treated with anti-TNF-α during the pregnancy period and reviewed the medical records to extract clinical details...
November 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28834393/drug-free-long-term-remission-in-severe-beh%C3%A3-et-s-disease-following-withdrawal-of-successful-anti-tumor-necrosis-factor-treatment
#14
Petros P Sfikakis, Aikaterini Arida, Stylianos Panopoulos, Kalliopi Fragiadaki, George Pentazos, Katerina Laskari, Maria Tektonidou, Nikos Markomichelakis
OBJECTIVE: To test the hypothesis that remission of Behçet's disease (BD) in patients with severe vital organ involvement is maintained after withdrawal of successful anti-tumor necrosis factor (anti-TNF) treatment. METHODS: This single-center, retrospective, longitudinal outcomes study focused on consecutive patients with disease refractory to treatment with conventional immunosuppressant agents who responded to add-on long-term anti-TNF treatment that was subsequently discontinued...
August 22, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28831751/discontinuation-of-biologic-therapy-in-rheumatoid-arthritis-analysis-from-the-corrona-ra-registry
#15
Vibeke Strand, Paul Miller, Setareh A Williams, Katherine Saunders, Shannon Grant, Joel Kremer
INTRODUCTION: Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons for discontinuation. METHODS: Inclusion criteria were: Corrona-registered adults (≥18 years) with RA (2002-2011); age of RA onset: ≥16 years; ≥6 months' follow-up after initiation of first/subsequent bDMARD...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28826571/indicators-of-suboptimal-tumor-necrosis-factor-antagonist-therapy-in-inflammatory-bowel-disease
#16
James O Lindsay, Alessandro Armuzzi, Javier P Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C Nguyen, Michael Smyth, Haridarshan Patel
BACKGROUND: Inflammatory bowel disease (IBD) is refractory to treatment in one-half of patients. AIMS: To evaluate the occurrence of suboptimal therapy among patients with IBD treated with tumor necrosis factor antagonists (anti-TNFs). METHODS: A multinational chart review in Europe and Canada was conducted among IBD patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who initiated anti-TNF therapy between 2009 and 2013...
August 1, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28818362/two-year-follow-up-of-crohn-s-patients-substituted-to-certolizumab-anti-tnfa-therapy-savant-2
#17
Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J Steven Alexander
The effectiveness of ant-TNF 'biologic' therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first 'SAVANT' study was to our knowledge the first study report one- year outcomes in patients (n=60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1...
August 9, 2017: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/28800384/exploring-conditions-for-redistribution-of-anti-tnfs-to-reduce-spillage-a-study-on-the-quality-of-anti-tnf-home-storage
#18
Marin J de Jong, Marieke J Pierik, Andy Peters, Mark Roemers, Veronique Hilhorst, Astrid van Tubergen
BACKGROUND AND AIM: Biologicals are potent drugs for immune mediated inflammatory diseases (IMIDs). After discontinuation or switch of therapy, many patients have unused biological injectors left. We aimed to evaluate potential redistribution of unused injectors to prevent spillage of these costly drugs by assessing 1) the quality of transport and home storage through the proportion of injectors stored within the recommended temperature range (2°C-8°C) and 2) acceptance of redistribution by patients...
August 11, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28764705/drug-survival-of-second-biological-dmard-therapy-in-patients-with-rheumatoid-arthritis-a-retrospective-non-interventional-cohort-analysis
#19
Thomas Wilke, Sabrina Mueller, Sze Chim Lee, Istvan Majer, Marieke Heisen
BACKGROUND: Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However, little is known about treatment persistence of the second-line bDMARD and it is specifically unknown whether the mode of action of such a treatment is associated with different persistence rates. We aimed to assess discontinuation-, re-initiation- or continuation-rates of a 2nd bDMARD therapy as well as switching-rates to a third biological DMARD (3rd bDMARD) therapy in RA patients...
August 2, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28752637/anti-tnf-treatment-in-crohn-s-disease-and-risk-of-bowel-resection-a-population-based-cohort-study
#20
M Eberhardson, J K Söderling, M Neovius, T Cars, P Myrelid, J F Ludvigsson, J Askling, A Ekbom, O Olén
BACKGROUND: TNF inhibitors (TNFi) have been shown to reduce the need for surgery in Crohn's disease, but few studies have examined their effect beyond the first year of treatment. AIM: To conduct a register-based observational cohort study in Sweden 2006-2014 to investigate the risk of bowel resection in bowel surgery naïve TNFi-treated Crohn's disease patients and whether patients on TNFi ≥12 months are less likely to undergo bowel resection than patients discontinuing treatment before 12 months...
September 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
61553
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"